No Data
No Data
Goldman Sachs Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating
Goldman Sachs analyst Chris Shibutani maintains $Neurocrine Biosciences(NBIX.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 44.1% and a total average return of 12
J.P. Morgan Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Raises Target Price to $169
J.P. Morgan analyst Anupam Rama maintains $Neurocrine Biosciences(NBIX.US)$ with a buy rating, and adjusts the target price from $158 to $169.According to TipRanks data, the analyst has a success rate
Neurocrine Is Maintained at Overweight by Morgan Stanley
Neurocrine Is Maintained at Overweight by Morgan Stanley
Neurocrine Biosciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/12/2024 19.11% Morgan Stanley $160 → $160 Maintains Overweight 05/29/2024 13.15% Wedbush $152 → $152 Re
Morgan Stanley Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $160
Morgan Stanley analyst Jeffrey Hung maintains $Neurocrine Biosciences(NBIX.US)$ with a buy rating, and maintains the target price at $160.According to TipRanks data, the analyst has a success rate of
Those Who Invested in Neurocrine Biosciences (NASDAQ:NBIX) Five Years Ago Are up 55%
The Real Wojak : Do you have like a top 3-5 that you like more than all the other ones? This list is way too long
72991267 : Glad I have some $Candel Therapeutics (CADL.US)$ after my disastrous SBFM.